{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-068304","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.906074+00:00","generated_at":"2026-06-01T06:31:51.888697+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari closes ~$7.6M private placement of ADSs and warrants","bullets":["Sold 3,817,553 ADSs and warrants at $1.885/unit to investors including chairman and interim CEO; 212,201 units to close later.","Warrants exercisable for 3 years at $1.76/ADS; insider warrants at $1.79/ADS.","Paid Paulson Investment Co. 8% cash fee and issued placement agent warrants for 332,380 ADSs at $1.885, 5-year term.","Company to file resale registration statement with SEC by June 28, 2024.","Securities issued under Section 4(a)(2) and Regulation D; accredited investors only."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-068304","json":"https://secwatch.observer/filing/0000950170-24-068304.json","markdown":"https://secwatch.observer/filing/0000950170-24-068304.md","text":"https://secwatch.observer/filing/0000950170-24-068304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/0000950170-24-068304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/aktx-20240529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:31:51.888697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}